Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.

ABSTRACT:

Importance

Preclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these findings.

Objective

To evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and craving in adults with alcohol use disorder (AUD).

Design, setting, and participants

This was a phase 2, double-blind, randomized, parallel-arm trial involving 9 weeks of outpatient treatment. Enrollment occurred at an academic medical center in the US from September 2022 to February 2024. Of 504 potential participants assessed, 48 non-treatment-seeking participants with AUD were randomized.

Intervention

Partici

SUBMITTER: Hendershot CS 

PROVIDER: S-EPMC11822619 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature